Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
SE

NASDAQ · SERA

Sera Prognostics, Inc.

Healthcare · Medical - Diagnostics & Research

$1.93

Up+$0.09 (+4.40%)

Updated Nov 4, 2026, 11:01 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
127.56M
P/E ratio
-5.15
Dividend yield
0.00%
52-week range
$1.56 – $2.46
Volume
14.96K
Avg. volume
44.27K

Price performance · SERA

SERA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

SERA closed at $1.93 after 21 trading sessions, down 5.85% for the selected period.

Last close
$1.93
Period change
-5.85%
Period low
$1.93
Period high
$2.07
Daily close
View OHLC price history
SERA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.96$2.05$1.93$1.9314.96K
Nov 2, 2026$2.05$2.07$1.96$1.9922.57K
Oct 30, 2026$2.09$2.10$2.03$2.0485.99K
Oct 29, 2026$2.095$2.095$2.03$2.0618.75K
Oct 28, 2026$2.03$2.03$2.03$2.03516
Oct 27, 2026$2.04$2.07$2.03$2.0513.57K
Oct 26, 2026$2.03$2.08$2.03$2.0425.42K
Oct 23, 2026$2.04$2.0999$2.03$2.0325.03K
Oct 22, 2026$2.03$2.04$2.03$2.0431.22K
Oct 21, 2026$2.03$2.045$2.03$2.0324.22K
Oct 20, 2026$2.06$2.06$2.025$2.0331.25K
Oct 19, 2026$2.04$2.065$2.03$2.035.28K
Oct 16, 2026$2.03$2.0612$2.03$2.064.28K
Oct 15, 2026$2.07$2.09$2.03$2.0313.3K
Oct 14, 2026$2.03$2.07$2.03$2.075.84K
Oct 13, 2026$2.04$2.0468$2.03$2.044.69K
Oct 12, 2026$2.06$2.099$2.03$2.0713.8K
Oct 9, 2026$2.01$2.10$2.01$2.046.3K
Oct 8, 2026$2.21$2.21$2.01$2.0213.38K
Oct 7, 2026$2.01$2.07$2.01$2.07772
Oct 6, 2026$2.12$2.12$2.02$2.054.39K

Latest SERA news

The latest Smart Investors Daily articles mentioning SERA.

Stock researchCompany · Overview

SERA research

Overview

Company profile and research snapshot.

Company profile

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$2.81
Implied upside
—
Analysts
8
SERA recent ratings
DateFirmRatingTarget
Jun 4, 2026Craig-HallumBuy—
Aug 10, 2023CitigroupNeutral—
Nov 10, 2022CitigroupNeutral—
Aug 29, 2022OppenheimerOutperform—
Apr 27, 2022BerenbergBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report its third quarter fiscal year 2026 financial results on Wednesday, November 4, 2026, after market close. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A pre

Yahoo · Aug 13, 2026

Sera Prognostics Q2 Earnings Call Highlights

Sera Prognostics (NASDAQ:SERA) reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform. Revenue for the quarter ended June 30 was $30,000, compared

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By